Napo Pharmaceuticals
Crofelemer
A proprietary gastro-intestinal compound in clinical development for four distinct product indications
 |
 |
 |
|
||
 |
|
 |
|
||
news
July 1, 2008
Total Voting Rights and Share Capital
Total Voting Rights and Share Capital
June 27, 2008
Issuance of US$0.12 Million Convertible Notes
Issuance of US$0.12 Million Convertible Notes
June 23, 2008
US $2.1 million fundraising and update on partnership discussions
US $2.1 million fundraising and update on partnership discussions
May 9, 2008
Napo presents at ISPOR meeting in Toronto
Napo presents at ISPOR meeting in Toronto
May 7, 2008
Napo RSA Announcement
Napo RSA Announcement
May 7, 2008
Share Purchase
Share Purchase
April 30, 2008
Napo Pharmaceuticals, Inc. 2007 Annual Report
Napo Pharmaceuticals, Inc. 2007 Annual Report
April 30, 2008
Napo Annual Report and Accounts
Napo Annual Report and Accounts
April 25, 2008
Share Purchases
Share Purchases
April 24, 2008
Share Purchase
Share Purchase
April 21, 2008
Share Purchase
Share Purchase
April 21, 2008
Interim Management Statement
Interim Management Statement
April 17, 2008
Results for the Year Ended 31 December 2007
Results for the Year Ended 31 December 2007
April 10, 2008
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
March 13, 2008
Admission to CREST
Admission to CREST
March 5, 2008
$2.55 Million Fundraising by Way of Issue of Convertible Debt and Common Shares
and $1.5 million Extension of Payment Terms with Certain Trade contractors
$2.55 Million Fundraising by Way of Issue of Convertible Debt and Common Shares and $1.5 million Extension of Payment Terms with Certain Trade contractors
February 28, 2008
Napo Licenses Patent from University of Iowa Research Foundation for Secretory Diarrhea
Napo Licenses Patent from University of Iowa Research Foundation for Secretory Diarrhea
February 19, 2008
Block Listing Six Monthly Return
February 11, 2008
Termination of Trine Agreement
Napo now in active discussions for commercial partner for crofelemer
Termination of Trine Agreement
Napo now in active discussions for commercial partner for crofelemer
February 6, 2008
Napo Receives Enteric Coated Formulation of Crofelemer Patent from United States Patent Office
Napo Receives Enteric Coated Formulation of Crofelemer Patent from United States Patent Office
February 4, 2008
Napo Appoints Dr. Jerome Ernst as Clinical Science Advisor
Napo Appoints Dr. Jerome Ernst as Clinical Science Advisor
January 7, 2008
Issue of Convertible Promissory Notes
Issue of Convertible Promissory Notes
December 4, 2007
Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
Glenmark Initiates Phase 2 Trial for Crofelemer for Acute Infectious Diarrhea
November 14, 2007
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
October 22. 2007
New Subs and Take Up of Funds Announcement
New Subs and Take Up of Funds Announcement
October 22. 2007
Annual Meeting Results
Annual Meeting Results
September 28, 2007
Placing and Subscription, Potential Further issue of Indicated Funds, Proposed Acquisition of Indus Pharmaceuticals, Inc and Block Listing of Shares
Placing and Subscription, Potential Further issue of Indicated Funds, Proposed Acquisition of Indus Pharmaceuticals, Inc and Block Listing of Shares
September 28, 2007
Interim Results for the Six Months Ended 30 June 2007
Interim Results for the Six Months Ended 30 June 2007
August 16, 2007
Napo Licenses CFTR Patents and Technology
Napo Licenses CFTR Patents and Technology
July 30, 2007
Appointment of VP Regulatory Affairs and Quality Assurance
Appointment of VP Regulatory Affairs and Quality Assurance
July 20, 2007
Transaction in Own Shares
Transaction in Own Shares
July 3, 2007
Napo Obtains Special Protocol Assessment
Agreement from FDA for Crofelemer in HIV/AIDS Diarrhea Assessment
Napo Obtains Special Protocol Assessment Agreement from FDA for Crofelemer in HIV/AIDS Diarrhea Assessment
June 28, 2007
Napo Pharmaceuticals, Inc. 2006 Annual Report
Napo Pharmaceuticals, Inc. 2006 Annual Report
June 15, 2007
Final Audited Results for the year ended December 31 2006- Reduction of Non-cash Stock-Based Compensation from Previously Released Preliminary Results
Final Audited Results for the year ended December 31 2006- Reduction of Non-cash Stock-Based Compensation from Previously Released Preliminary Results
June 14, 2007
Updated Statement of Total Voting Rights and Share Capital
Updated Statement of Total Voting Rights and Share Capital
June 12, 2007
Appointment of Thomas Van Dyck as Non-Executive Director
Appointment of Thomas Van Dyck as Non-Executive Director
May 23, 2007
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington D.C.
Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington D.C.
May 21, 2007
Ethics Committee Approval Granted for Multiple- Dose Continuation of Phase 2 Clinical Trial of Crofelemer for Treatment of Secretory Diarrhea Associated with Cholera Infection
Ethics Committee Approval Granted for Multiple- Dose Continuation of Phase 2 Clinical Trial of Crofelemer for Treatment of Secretory Diarrhea Associated with Cholera Infection
May 15, 2007
Napo Confirms Satisfaction of Conditions of Conditional Private Placement of Common Shares
Napo Confirms Satisfaction of Conditions of Conditional Private Placement of Common Shares
April 23, 2007
Napo Pharmaceuticals, Inc. Announces Board Changes
Napo Pharmaceuticals, Inc. Announces Board Changes
April 20, 2007
Proposed Board Changes
Proposed Board Changes
April 19, 2007
Napo Appointment and Removal of Directors and the Calling of an Extraordinary General Meeting
Napo Appointment and Removal of Directors and the Calling of an Extraordinary General Meeting
March 30, 2007
Preliminary Results for the Year Ended 31 December 2006
Preliminary Results for the Year Ended 31 December 2006
March 14, 2007
Napo Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer in HIV/AIDS Diarrhea Assessment
Napo Obtains IRB Approval for Phase 3 Clinical Trial Protocol for Crofelemer in HIV/AIDS Diarrhea Assessment
March 6, 2007
Appointment of Jack Van Hulst as Non-Executive Director
Appointment of Jack Van Hulst as Non-Executive Director
February 15, 2007
Postive Progress with Cholera Clinical Trial for Treatment of Secretory Diarrhea Associated with Cholera Infection
Postive Progress with Cholera Clinical Trial for Treatment of Secretory Diarrhea Associated with Cholera Infection
January 22, 2007
Collaboration with Nicholas Piramal
Collaboration with Nicholas Piramal
January 19, 2007
Updated Statement of Total Voting Rights
Updated Statement of Total Voting Rights
January 18, 2007
Transaction in Own Shares
Transaction in Own Shares
January 12, 2007
Notification of Transactions
Notification of Transactions
January 12, 2007
Appointment of COO
Appointment of COO
January 10, 2007
Application for Admission
Application for Admission
January 10, 2007
Appointment of Board Member
Appointment of Board Member
January 8, 2007
Napo Receives Commitments for a Private
Placement of Common Shares and Enters into
Binding Letter of Intent for Intellectual Property License
Napo Receives Commitments for a Private Placement of Common Shares and Enters into Binding Letter of Intent for Intellectual Property License
December 21, 2006
Total Voting Rights and Share Capital
Total Voting Rights and Share Capital
December 20, 2006
Napo Completes Feasibility Assessment
Napo Completes Feasibility Assessment
December 1, 2006
Block Listing of Shares - Further Clarification
Block Listing of Shares - Further Clarification
December 1, 2006
Block Listing of Shares
Block Listing of Shares
November 17, 2006
Napo Announces Successful Production of Crofelemer
Napo Announces Successful Production of Crofelemer
November 8, 2006
Appointment of VP Clinical Affairs and Chief Medical Officer
Appointment of VP Clinical Affairs and Chief Medical Officer
November 2, 2006
Appointment of VP Program Planning and Management
Appointment of VP Program Planning and Management
October 30, 2006
Trine Initiates Phase 2b Trial for D-IBS
Napo to Receive $1 million Milestone Payment
Trine Initiates Phase 2b Trial for D-IBS
Napo to Receive $1 million Milestone Payment
September 29, 2006
Napo Issued Share Capital September 29, 2006
Napo Issued Share Capital September 29, 2006
September 28, 2006
Napo Issued Share Capital September 28, 2006
Napo Issued Share Capital September 28, 2006
September 15, 2006
Interim Results for the Six Months ended June 30, 2006
Interim Results for the Six Months ended June 30, 2006
August 3, 2006
Napo Pharmaceuticals, Inc. Receives Approval From Indian Regulator To Initiate
Phase II Clinical Trial For Crofelemer For Acute Infectious Diarrhea In Adult
Patients
Napo Pharmaceuticals, Inc. Receives Approval From Indian Regulator To Initiate Phase II Clinical Trial For Crofelemer For Acute Infectious Diarrhea In Adult Patients
August 2, 2006
London Stock Exchange Welcomes
First Us-Incorporated Company To IPO On The Main Market
London Stock Exchange Welcomes First Us-Incorporated Company To IPO On The Main Market
July 31, 2006
Napo Pharmaceuticals, Inc. admitted to trading
on the Main Market of the London Stock Exchange
Napo Pharmaceuticals, Inc. admitted to trading on the Main Market of the London Stock Exchange
If you would like to receive e-mail alerts when we send out press releases, please send an e-mail to news@napopharma.com with the subject 'subscribe'.
